Muscle damage has been shown to enhance the contribution of bone marrow–derived cells (BMDCs) to regenerating skeletal muscle. One responsible cell type involved in this process is a hematopoietic stem cell derivative, the myelomonocytic precursor (MMC). However, the molecular components responsible for this injury-related response remain largely unknown. In this paper, we show that delivery of insulin-like growth factor I (IGF-I) to adult skeletal muscle by three different methods—plasmid electroporation, injection of genetically engineered myoblasts, and recombinant protein injection—increases the integration of BMDCs up to fourfold. To investigate the underlying mechanism, we developed an in vitro fusion assay in which co-cultures of MMCs and myotubes were exposed to IGF-I. The number of fusion events was substantially augmented by IGF-I, independent of its effect on cell survival. These results provide novel evidence that a single factor, IGF-I, is sufficient to enhance the fusion of bone marrow derivatives with adult skeletal muscle.
Skip Nav Destination
Article navigation
7 November 2005
Article Contents
Article|
November 07 2005
IGF-I increases bone marrow contribution to adult skeletal muscle and enhances the fusion of myelomonocytic precursors
Alessandra Sacco,
Alessandra Sacco
1Department of Molecular Pharmacology, Baxter Laboratory in Genetic Pharmacology, Stanford University School of Medicine, Stanford, CA 94305
Search for other works by this author on:
Regis Doyonnas,
Regis Doyonnas
1Department of Molecular Pharmacology, Baxter Laboratory in Genetic Pharmacology, Stanford University School of Medicine, Stanford, CA 94305
Search for other works by this author on:
Mark A. LaBarge,
Mark A. LaBarge
2Department of Microbiology and Immunology, Baxter Laboratory in Genetic Pharmacology, Stanford University School of Medicine, Stanford, CA 94305
Search for other works by this author on:
Mark M. Hammer,
Mark M. Hammer
1Department of Molecular Pharmacology, Baxter Laboratory in Genetic Pharmacology, Stanford University School of Medicine, Stanford, CA 94305
2Department of Microbiology and Immunology, Baxter Laboratory in Genetic Pharmacology, Stanford University School of Medicine, Stanford, CA 94305
Search for other works by this author on:
Peggy Kraft,
Peggy Kraft
1Department of Molecular Pharmacology, Baxter Laboratory in Genetic Pharmacology, Stanford University School of Medicine, Stanford, CA 94305
2Department of Microbiology and Immunology, Baxter Laboratory in Genetic Pharmacology, Stanford University School of Medicine, Stanford, CA 94305
Search for other works by this author on:
Helen M. Blau
Helen M. Blau
1Department of Molecular Pharmacology, Baxter Laboratory in Genetic Pharmacology, Stanford University School of Medicine, Stanford, CA 94305
2Department of Microbiology and Immunology, Baxter Laboratory in Genetic Pharmacology, Stanford University School of Medicine, Stanford, CA 94305
Search for other works by this author on:
Alessandra Sacco
1Department of Molecular Pharmacology, Baxter Laboratory in Genetic Pharmacology, Stanford University School of Medicine, Stanford, CA 94305
Regis Doyonnas
1Department of Molecular Pharmacology, Baxter Laboratory in Genetic Pharmacology, Stanford University School of Medicine, Stanford, CA 94305
Mark A. LaBarge
2Department of Microbiology and Immunology, Baxter Laboratory in Genetic Pharmacology, Stanford University School of Medicine, Stanford, CA 94305
Mark M. Hammer
1Department of Molecular Pharmacology, Baxter Laboratory in Genetic Pharmacology, Stanford University School of Medicine, Stanford, CA 94305
2Department of Microbiology and Immunology, Baxter Laboratory in Genetic Pharmacology, Stanford University School of Medicine, Stanford, CA 94305
Peggy Kraft
1Department of Molecular Pharmacology, Baxter Laboratory in Genetic Pharmacology, Stanford University School of Medicine, Stanford, CA 94305
2Department of Microbiology and Immunology, Baxter Laboratory in Genetic Pharmacology, Stanford University School of Medicine, Stanford, CA 94305
Helen M. Blau
1Department of Molecular Pharmacology, Baxter Laboratory in Genetic Pharmacology, Stanford University School of Medicine, Stanford, CA 94305
2Department of Microbiology and Immunology, Baxter Laboratory in Genetic Pharmacology, Stanford University School of Medicine, Stanford, CA 94305
Correspondence to Helen M. Blau: [email protected]
M.A. LaBarge's present address is Lawrence Berkeley National Laboratory, Berkeley, CA 94720.
Abbreviations used in this paper: β-gal, β-galactosidase; BMDC, bone marrow–derived cell; BMT, bone marrow transplant; DM, differentiation medium; GM, growth medium; HSC, hematopoietic stem cell; IGF-I, insulin-like growth factor I; MGF, mechano growth factor; MMC, myelomonocytic precursor; TA, tibialis anterior.
Received:
June 02 2005
Accepted:
October 04 2005
Online ISSN: 1540-8140
Print ISSN: 0021-9525
The Rockefeller University Press
2005
J Cell Biol (2005) 171 (3): 483–492.
Article history
Received:
June 02 2005
Accepted:
October 04 2005
Citation
Alessandra Sacco, Regis Doyonnas, Mark A. LaBarge, Mark M. Hammer, Peggy Kraft, Helen M. Blau; IGF-I increases bone marrow contribution to adult skeletal muscle and enhances the fusion of myelomonocytic precursors . J Cell Biol 7 November 2005; 171 (3): 483–492. doi: https://doi.org/10.1083/jcb.200506123
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionSuggested Content
Email alerts
Advertisement
